Skip to main content

Table 2 Delayed type hypersensitivity response to PPD during first cycle of study a

From: Thalidomide Treatment Reduces Tumor Necrosis Factor α Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis

Patient Number Skin Test Response to PPD (mm)b
Pre Mid Post
PPD+    
1 26.5 20.5 24.0
3 14.0 25.0 18.5
4 19.0 16.0 20.5
5 16.5 18.0 24.5
6 14.0 12.0 16.5
7 23.5 65.0 NDc
9 18.5 14.5 21.5
11 14.5 18.0 13.0
12 19.5 26.0 17.0
13d 15.0 21.0 26.0
14d 26.5 22.0 31.0
15 16.0 18.0 10.0
16d 26.0 22.5 23.0
18d 20.0 20.5 17.0
19 15.5 18.0 16.0
20d ND ND ND
21 11.0 15.5 12.0
22 22.0 19.0 17.0
23d ND ND ND
25 ND ND ND
26 19.0 ND ND
27 13.0 14.5 18.0
28 13.0 12.5 17.5
29d 18.0 14.0 10.0
PPD    
2 0 9.5 0
8 0 19.5 0
10 0 12.5 0
17 0 9.0 11.5
24d 0 0 0
30 0 19.0 ND
  1. aPatients in Thailand and New York were skin tested 3× during the first cycle of study.
  2. bMean diameter of the indurated area at 48 hr after 5 u PPD administration. Diameter >10 mm is termed PPD+. cND, not done.
  3. dPatients received placebo during the first cycle of study.